Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth (Status and Outlook) 2025-2031
According to this study, the global Benign Prostatic Hyperplasia (BPH) Treatment market size will reach US$ 3887 million by 2031.
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia (BPH) Treatment Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Treatment sales for 2025 through 2031. With Benign Prostatic Hyperplasia (BPH) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia (BPH) Treatment Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Treatment sales for 2025 through 2031. With Benign Prostatic Hyperplasia (BPH) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Alpha-Blocker
- Phosphodiesterase Type-5 Inhibitors
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Eli Lilly
- GlaxoSmithKline
- Astellas Pharma
- Sanofi
- Viatris
- Abbott
- Allergan
- TEVA
- Novartis
- Merck
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2020-2031)
2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Treatment by Country/Region (2020, 2024 & 2031)
2.2 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
2.3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
2.4 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
2.5.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
3 BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT MARKET SIZE BY PLAYER
3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Player
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT BY REGION
4.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025)
4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.4 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.5 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
5.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
6.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment by Region (2020-2025)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT MARKET FORECAST
10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.1.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Country (2026-2031)
10.2.1 United States Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.2 Canada Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.3 Mexico Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.4 Brazil Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.3.1 China Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast
10.3.2 Japan Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.3 Korea Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.4 Southeast Asia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.5 India Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.6 Australia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Country (2026-2031)
10.4.1 Germany Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.2 France Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.3 UK Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.4 Italy Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.5 Russia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.5.1 Egypt Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.2 South Africa Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.3 Israel Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.4 Turkey Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.6 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Type (2026-2031)
10.7 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
11 KEY PLAYERS ANALYSIS
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Eli Lilly Main Business Overview
11.1.5 Eli Lilly Latest Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 GlaxoSmithKline Main Business Overview
11.2.5 GlaxoSmithKline Latest Developments
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Information
11.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Astellas Pharma Main Business Overview
11.3.5 Astellas Pharma Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Viatris
11.5.1 Viatris Company Information
11.5.2 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.5.3 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Viatris Main Business Overview
11.5.5 Viatris Latest Developments
11.6 Abbott
11.6.1 Abbott Company Information
11.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Abbott Main Business Overview
11.6.5 Abbott Latest Developments
11.7 Allergan
11.7.1 Allergan Company Information
11.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Allergan Main Business Overview
11.7.5 Allergan Latest Developments
11.8 TEVA
11.8.1 TEVA Company Information
11.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 TEVA Main Business Overview
11.8.5 TEVA Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.9.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.10.3 Merck Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2020-2031)
2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Treatment by Country/Region (2020, 2024 & 2031)
2.2 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
2.3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
2.4 Benign Prostatic Hyperplasia (BPH) Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application
2.5.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
3 BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT MARKET SIZE BY PLAYER
3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Player
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT BY REGION
4.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025)
4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.4 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.5 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
5.3 Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
6.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment by Region (2020-2025)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT MARKET FORECAST
10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.1.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.1.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2 Americas Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Country (2026-2031)
10.2.1 United States Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.2 Canada Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.3 Mexico Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.2.4 Brazil Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3 APAC Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.3.1 China Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast
10.3.2 Japan Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.3 Korea Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.4 Southeast Asia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.5 India Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.3.6 Australia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Country (2026-2031)
10.4.1 Germany Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.2 France Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.3 UK Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.4 Italy Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.4.5 Russia Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Region (2026-2031)
10.5.1 Egypt Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.2 South Africa Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.3 Israel Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.5.4 Turkey Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
10.6 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Type (2026-2031)
10.7 Global Benign Prostatic Hyperplasia (BPH) Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Benign Prostatic Hyperplasia (BPH) Treatment Forecast
11 KEY PLAYERS ANALYSIS
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Eli Lilly Main Business Overview
11.1.5 Eli Lilly Latest Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 GlaxoSmithKline Main Business Overview
11.2.5 GlaxoSmithKline Latest Developments
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Information
11.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Astellas Pharma Main Business Overview
11.3.5 Astellas Pharma Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Viatris
11.5.1 Viatris Company Information
11.5.2 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.5.3 Viatris Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Viatris Main Business Overview
11.5.5 Viatris Latest Developments
11.6 Abbott
11.6.1 Abbott Company Information
11.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Abbott Main Business Overview
11.6.5 Abbott Latest Developments
11.7 Allergan
11.7.1 Allergan Company Information
11.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Allergan Main Business Overview
11.7.5 Allergan Latest Developments
11.8 TEVA
11.8.1 TEVA Company Information
11.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 TEVA Main Business Overview
11.8.5 TEVA Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.9.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
11.10.3 Merck Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Treatment Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Alpha-Blocker
Table 4. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 5. Major Players of Others
Table 6. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Table 9. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player (2020-2025)
Table 14. Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
Table 15. Benign Prostatic Hyperplasia (BPH) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country (2020-2025)
Table 24. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Table 26. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Table 28. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Table 30. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country (2020-2025)
Table 34. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Treatment
Table 40. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Treatment
Table 41. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Treatment
Table 42. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. Eli Lilly Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 47. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 48. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. Eli Lilly Main Business
Table 50. Eli Lilly Latest Developments
Table 51. GlaxoSmithKline Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 52. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 53. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. GlaxoSmithKline Main Business
Table 55. GlaxoSmithKline Latest Developments
Table 56. Astellas Pharma Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 57. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 58. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Astellas Pharma Main Business
Table 60. Astellas Pharma Latest Developments
Table 61. Sanofi Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 62. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 63. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Sanofi Main Business
Table 65. Sanofi Latest Developments
Table 66. Viatris Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 67. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 68. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Viatris Main Business
Table 70. Viatris Latest Developments
Table 71. Abbott Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 72. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 73. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Abbott Main Business
Table 75. Abbott Latest Developments
Table 76. Allergan Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 77. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 78. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Allergan Main Business
Table 80. Allergan Latest Developments
Table 81. TEVA Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 82. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 83. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. TEVA Main Business
Table 85. TEVA Latest Developments
Table 86. Novartis Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 87. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 88. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 89. Novartis Main Business
Table 90. Novartis Latest Developments
Table 91. Merck Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 92. Merck Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 93. Merck Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 94. Merck Main Business
Table 95. Merck Latest Developments
Table 1. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Treatment Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Alpha-Blocker
Table 4. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 5. Major Players of Others
Table 6. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Table 9. Benign Prostatic Hyperplasia (BPH) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player (2020-2025)
Table 14. Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Products Offered
Table 15. Benign Prostatic Hyperplasia (BPH) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country (2020-2025)
Table 24. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 25. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Table 26. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Table 28. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Table 30. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 31. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country (2020-2025)
Table 34. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 35. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2020-2025) & ($ millions)
Table 38. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Treatment
Table 40. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Treatment
Table 41. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Treatment
Table 42. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Region (2026-2031) & ($ millions)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Region (2026-2031)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Type (2026-2031) & ($ millions)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast by Application (2026-2031) & ($ millions)
Table 46. Eli Lilly Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 47. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 48. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. Eli Lilly Main Business
Table 50. Eli Lilly Latest Developments
Table 51. GlaxoSmithKline Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 52. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 53. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. GlaxoSmithKline Main Business
Table 55. GlaxoSmithKline Latest Developments
Table 56. Astellas Pharma Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 57. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 58. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Astellas Pharma Main Business
Table 60. Astellas Pharma Latest Developments
Table 61. Sanofi Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 62. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 63. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Sanofi Main Business
Table 65. Sanofi Latest Developments
Table 66. Viatris Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 67. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 68. Viatris Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Viatris Main Business
Table 70. Viatris Latest Developments
Table 71. Abbott Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 72. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 73. Abbott Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Abbott Main Business
Table 75. Abbott Latest Developments
Table 76. Allergan Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 77. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 78. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Allergan Main Business
Table 80. Allergan Latest Developments
Table 81. TEVA Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 82. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 83. TEVA Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. TEVA Main Business
Table 85. TEVA Latest Developments
Table 86. Novartis Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 87. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 88. Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 89. Novartis Main Business
Table 90. Novartis Latest Developments
Table 91. Merck Details, Company Type, Benign Prostatic Hyperplasia (BPH) Treatment Area Served and Its Competitors
Table 92. Merck Benign Prostatic Hyperplasia (BPH) Treatment Product Offered
Table 93. Merck Benign Prostatic Hyperplasia (BPH) Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 94. Merck Main Business
Table 95. Merck Latest Developments
LIST OF FIGURES
Figure 1. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Benign Prostatic Hyperplasia (BPH) Treatment Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Country/Region (2024)
Figure 8. Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type in 2024
Figure 10. Benign Prostatic Hyperplasia (BPH) Treatment in Hospital Pharmacies
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Hospital Pharmacies (2020-2025) & ($ millions)
Figure 12. Benign Prostatic Hyperplasia (BPH) Treatment in Retail Pharmacies
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Retail Pharmacies (2020-2025) & ($ millions)
Figure 14. Benign Prostatic Hyperplasia (BPH) Treatment in Online Pharmacies
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Online Pharmacies (2020-2025) & ($ millions)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application in 2024
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player in 2024
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Figure 19. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 20. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 23. Americas Benign Prostatic Hyperplasia (BPH) Treatment Value Market Share by Country in 2024
Figure 24. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region in 2024
Figure 29. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 31. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 35. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country in 2024
Figure 38. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 39. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 40. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 41. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 54. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 57. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 58. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 59. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 60. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 61. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 62. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 63. Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 65. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 66. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 67. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 68. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 69. UK Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 70. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 71. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 72. Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 73. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 74. Israel Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 75. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 76. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 1. Benign Prostatic Hyperplasia (BPH) Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Benign Prostatic Hyperplasia (BPH) Treatment Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Country/Region (2024)
Figure 8. Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type in 2024
Figure 10. Benign Prostatic Hyperplasia (BPH) Treatment in Hospital Pharmacies
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Hospital Pharmacies (2020-2025) & ($ millions)
Figure 12. Benign Prostatic Hyperplasia (BPH) Treatment in Retail Pharmacies
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Retail Pharmacies (2020-2025) & ($ millions)
Figure 14. Benign Prostatic Hyperplasia (BPH) Treatment in Online Pharmacies
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Online Pharmacies (2020-2025) & ($ millions)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application in 2024
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Player in 2024
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Figure 19. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 20. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2020-2025 ($ millions)
Figure 23. Americas Benign Prostatic Hyperplasia (BPH) Treatment Value Market Share by Country in 2024
Figure 24. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region in 2024
Figure 29. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 31. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 35. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Country in 2024
Figure 38. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 39. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 40. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 41. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 54. APAC Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 57. United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 58. Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 59. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 60. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 61. China Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 62. Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 63. Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 65. India Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 66. Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 67. Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 68. France Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 69. UK Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 70. Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 71. Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 72. Egypt Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 73. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 74. Israel Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 75. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
Figure 76. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Benign Prostatic Hyperplasia (BPH) Treatment Market Size 2026-2031 ($ millions)
